Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?

Colorectal cancer (CRC) is the third most commonly diagnosed malignancy worldwide and is responsible as one of the main causes of mortality in both men and women. Despite massive efforts to raise public awareness on early screening and significant advancements in the treatment for CRC, the majority...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hidayati Husainy Hasbullah, Marahaini Musa
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	colon cancer mutation p53 KRAS targeted therapy Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/b4a1bfebaeec44c18aa6dfaa0dbf5002
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b4a1bfebaeec44c18aa6dfaa0dbf5002
record_format	dspace
spelling	oai:doaj.org-article:b4a1bfebaeec44c18aa6dfaa0dbf50022021-11-11T17:21:32ZGene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?10.3390/ijms2221119411422-00671661-6596https://doaj.org/article/b4a1bfebaeec44c18aa6dfaa0dbf50022021-11-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/21/11941https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067Colorectal cancer (CRC) is the third most commonly diagnosed malignancy worldwide and is responsible as one of the main causes of mortality in both men and women. Despite massive efforts to raise public awareness on early screening and significant advancements in the treatment for CRC, the majority of cases are still being diagnosed at the advanced stage. This contributes to low survivability due to this cancer. CRC patients present various genetic changes and epigenetic modifications. The most common genetic alterations associated with CRC are p53 and KRAS mutations. Gene therapy targeting defect genes such as <i>TP53</i> (tumor suppressor gene encodes for p53) and <i>KRAS</i> (oncogene) in CRC potentially serves as an alternative treatment avenue for the disease in addition to the standard therapy. For the last decade, significant developments have been seen in gene therapy for translational purposes in treating various cancers. This includes the development of vectors as delivery vehicles. Despite the optimism revolving around targeted gene therapy for cancer treatment, it also has various limitations, such as a lack of availability of related technology, high cost of the involved procedures, and ethical issues. This article will provide a review on the potentials and challenges of gene therapy targeting p53 and KRAS for the treatment of CRC.Hidayati Husainy HasbullahMarahaini MusaMDPI AGarticlecolon cancermutationp53KRAStargeted therapyBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 11941, p 11941 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	colon cancer mutation p53 KRAS targeted therapy Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	colon cancer mutation p53 KRAS targeted therapy Biology (General) QH301-705.5 Chemistry QD1-999 Hidayati Husainy Hasbullah Marahaini Musa Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
description	Colorectal cancer (CRC) is the third most commonly diagnosed malignancy worldwide and is responsible as one of the main causes of mortality in both men and women. Despite massive efforts to raise public awareness on early screening and significant advancements in the treatment for CRC, the majority of cases are still being diagnosed at the advanced stage. This contributes to low survivability due to this cancer. CRC patients present various genetic changes and epigenetic modifications. The most common genetic alterations associated with CRC are p53 and KRAS mutations. Gene therapy targeting defect genes such as <i>TP53</i> (tumor suppressor gene encodes for p53) and <i>KRAS</i> (oncogene) in CRC potentially serves as an alternative treatment avenue for the disease in addition to the standard therapy. For the last decade, significant developments have been seen in gene therapy for translational purposes in treating various cancers. This includes the development of vectors as delivery vehicles. Despite the optimism revolving around targeted gene therapy for cancer treatment, it also has various limitations, such as a lack of availability of related technology, high cost of the involved procedures, and ethical issues. This article will provide a review on the potentials and challenges of gene therapy targeting p53 and KRAS for the treatment of CRC.
format	article
author	Hidayati Husainy Hasbullah Marahaini Musa
author_facet	Hidayati Husainy Hasbullah Marahaini Musa
author_sort	Hidayati Husainy Hasbullah
title	Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
title_short	Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
title_full	Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
title_fullStr	Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
title_full_unstemmed	Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
title_sort	gene therapy targeting p53 and kras for colorectal cancer treatment: a myth or the way forward?
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/b4a1bfebaeec44c18aa6dfaa0dbf5002
work_keys_str_mv	AT hidayatihusainyhasbullah genetherapytargetingp53andkrasforcolorectalcancertreatmentamythorthewayforward AT marahainimusa genetherapytargetingp53andkrasforcolorectalcancertreatmentamythorthewayforward
_version_	1718432140243238912

Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?

Ejemplares similares